Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13859MR)

This product GTTS-WQ13859MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13859MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15144MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ12890MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ10175MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ4042MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ8234MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ15613MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ11680MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ2573MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW